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Abstract
Background: Alcoholic Hepatitis (AH) is major source of alcohol-related mortality and health care expenditures in
the United States. There is insufficient information regarding the role of race and ethnicity on healthcare utilization
and outcomes for patients with AH. We aimed to determine whether there are racial/ethnic differences in resource
utilization and inpatient mortality in patients hospitalized with AH.
Methods: We analyzed data from the Nationwide Inpatient Sample (NIS), years 2008–2011. We calculated
demographic, clinical, and healthcare utilization characteristics by race. We then performed logistic regression and
generalized linear modeling with gamma distribution (log link), respectively, to determine predictors of inpatient
morality and total hospital costs (THC).
Results: We identified 11,304 AH patients from 2008 to 2011. Mean age was 47.0 years, and 62.1 % were male, 61.
9 % were white, 9.8 % were black, and 9.7 % were Hispanic. Mean LOS was 6.3 days and significantly longer in
whites (6.5 d) than both blacks (5.4 d) and Hispanics (5.9 d). In adjusted models, inpatient mortality was lower for
blacks than for whites (adj. OR = 0.50; 95 % CI = 0.32–0.78). THC was significantly higher for Hispanics than whites
(fold increase = 1.25; 95 % CI = 1.01–1.49).
Conclusions: We identified differences in healthcare utilization and mortality by race/ethnicity. THC was
significantly higher among Hispanics than for whites and blacks. We also demonstrated lower inpatient mortality in
blacks compared to whites. These variations may implicate racial and ethnic differences in access to care, quality of
care, severity of AH on presentation, or other factors.
Keywords: Liver disease, Nationwide inpatient sample, Disparities, Healthcare utilization, Alcoholic hepatitis
Background
Alcoholic hepatitis (AH) is a major cause of alcohol-
related morbidity and mortality in the United States
(U.S.) [1, 2]. Characterized by acute liver inflammation
in the setting of chronic alcohol use, AH carries a poor
prognosis with a 30-day mortality as high as 30 %,
depending on the severity of disease [3–5]. AH also
poses significant burden on healthcare utilization and
costs in the U.S. National data demonstrate that
inpatient healthcare expenditures associated with AH
may exceed spending for other chronic liver disease
states, including hepatitis C (HCV) and hepatocellular
carcinoma (HCC) [1, 6, 7]. As effective treatment is
lacking for this condition, the mortality, healthcare costs,
and utilization related to AH are unlikely to improve in
the near future.
There is increasing emphasis on improving health
equity and addressing healthcare disparities regarding
race and ethnicity in the U.S. [8]. Current literature
documents racial and ethnic disparities in mortality,
prevalence, and healthcare utilization in several chronic
liver disease states [9–13]. For example, blacks are less
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likely than white Americans to undergo screening for
HCV and more likely than white Americans to die from
HCV-related complications [11]. Studies have similarly
demonstrated Hispanic Americans to have a greater
prevalence of non-alcoholic fatty liver disease and an
increased risk of developing HCC when compared to
caucasians and blacks [9, 10, 12, 13].
While racial/ethnic variation in healthcare outcomes
and utilization has been explored in many chronic liver
disease states, there is a paucity of literature regarding the
impact of these factors in relation to alcoholic hepatitis
[14]. In this study, we aimed to determine whether there
are racial and ethnic differences in inpatient mortality and
health service utilization among patients hospitalized for
AH in the U.S, using a large nationwide database.
Methods
Source of data
We performed a retrospective cross-sectional study using
the Nationwide Inpatient Sample (NIS), years 2008–2011
[15]. The NIS is the largest publicly available inpatient
database and includes a 20 % stratified sample of all U.S.
inpatient discharges occurring in a given year from approxi-
mately 1000 non-federal U.S. hospitals in 42 to 47 states,
depending on the year. Each hospital included in the NIS
participates in the Agency for Healthcare Research and
Quality Healthcare Cost and Utilization Project. Each dis-
charge record from the NIS contains associated patient and
hospital demographic information, primary and up to 24
secondary discharge diagnoses, and up to 15 procedural
codes. The study protocol was approved as exempt from
review by the institutional review board of Cedars-Sinai
Medical Center.
Study population
The study sample included inpatients age 18 years or older
with a primary discharge diagnosis of AH. As per
previously published studies utilizing administrative data to
identify patients with AH, we used the International Classi-
fication of Diseases, 9th revision, Clinical Modification
(ICD-9-CM) code 571.1 to identify our AH sample [2, 16].
Variables
Our main outcomes were inpatient mortality, total
hospital costs (THC), length of hospital stay (LOS), and
number of procedures performed (NPR). THCs were
inflated to 2011 values for years 2008, 2009, and 2010
using the consumer price index (CPI) [7]. We also
accounted for inpatient procedures used in the manage-
ment of AH, including nasogastric intubation (NGT),
mechanical ventilation (MV), hemodialysis, esophago-
gastroduodenoscopy (EGD), paracentesis, liver biopsy,
and liver transplantation.
Additional patient-level data included patient age, sex,
race/ethnicity, socioeconomic status (SES), insurance type
(Medicare, Medicaid, private, self-pay, other), comorbidity,
source of admission (emergency room (ER), hospital
transfer, other health-related facility, other non-health
facility), and disposition at discharge (home or home with
aid, other health facility, and other). For SES, we used in-
come strata. For race, categories included white, black,
Hispanic, and other (Asian, Pacific islander, Native Ameri-
can, or another race). Hospital characteristics in the ana-
lysis included hospital region (Northeast, South, Midwest,
West), hospital type (teaching, nonteaching), and hospital
setting (urban, rural).
We used the Deyo modification of the Charlson index
as a proxy for patient comorbidity [17, 18]. We stratified
the Charlson index into 3 groups to represent the degree
of comorbidity: Mild (score = 0), moderate (score = 1–3),
and severe (score > 3). In addition, we used the Baveno
IV consensus criteria as a measure for severity of liver
disease, where patients were categorized as stage 1 (no
esophageal varices or ascites), stage 2 (esophageal
varices, no ascites or bleeding), stage 3 (ascites, with or
without esophageal varices), or stage 4 (history of gastro-
intestinal bleeding with or without ascites) [19]. Stage 1
and 2 disease represented compensated cirrhosis; stage 3
and 4 disease represented decompensated cirrhosis. As
greater than 90 % of patients with biopsy-proven AH
have underlying liver cirrhosis, this classification system
is applicable to our study population [20].
We also accounted for known conditions that might
impact AH outcomes, including ascites, HCV infection,
gastrointestinal bleeding, hepatic encephalopathy, and
bacterial infection (ICD-9 codes are provided in Additional
file 1: Table S1) [21]. For infection, we created one variable
that included all ICD-9-CM codes for bacterial infections
potentially treated with antibiotics, similar to methodology
used in previously published studies (ICD-9 codes are
provided in Additional file 1: Table S1) [16, 22].
Statistical analyses
We described patient descriptive and clinical character-
istics as means with standard deviation or medians with
interquartile ranges for Gaussian and non-Gaussian
distributed variables, respectively. For crude statistical
comparisons, we used the chi-square test for categorical
variables, student’s t-test and one-way analysis of
variance (ANOVA) with the Tukey-Kramer method to
compare continuous variables, and the Wilcoxon-Rank
sum test for non-Gaussian distributed variables, all with
the Bonferroni correction for multiple comparisons. For
THC, LOS and NPR, we computed regional compari-
sons of means by quantile regression.
Following descriptive analyses, we determined signifi-
cant predictors of inpatient mortality and THC among
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patients admitted to U.S. hospitals with AH. We used
multiple imputation for missing values for hospital
admission source (19 % missing), discharge disposition
(14 % missing), and race (14 % missing) using 20
imputed datasets. Other missing values were less than
5 % and were not imputed [23]. For mortality, we used
logistic regression, controlling for patient demographic
and clinical factors, to determine the impact of race/eth-
nicity on inpatient mortality among patients admitted
with a primary diagnosis of AH. Second, we performed a
generalized linear model (GLM) with gamma distribu-
tion and log link to examine the relationship between
race/ethnicity and THC. GLM was felt appropriate in the
present analysis given that THC is a heavily skewed, non-
integer outcome. GLM compares the log of THC across
groups while controlling for covariates in the model.
Thus, the antilog of the parameters of the linear regres-
sion model can be interpreted as the fold increase in THC
between groups being compared. For both regression
models, covariates were selected based on significance in
univariate analysis at the p <0.05 level or clinical
experience and consistent prior data supporting their
association. We used southern region as the reference
geographic region as it was the region with the lowest
mean value for THC based on unadjusted analysis.
Analyses were performed with STATA 13.1 software
(Stata Corp, College Station, TX) with the appropriate
survey estimation commands and strata weights pro-
vided in each NIS file. To represent national population
estimates, we applied survey weights to the patient-level
observations in the dataset. A p-value less than 0.05 on
two-tailed testing was considered significant except in
cases where the Bonferroni correction was indicated.
Results
Characteristics of study population
Table 1 provides demographic and clinical characteristics
of the study sample of 11,304 AH patients, stratified by
geographic region. Most of the patients were white
(61.9 %), followed by black (9.8 %), and Hispanic (9.7 %).
Mean age at admission was slightly lower in the Hispanic
population (43.7 years) than in the white group (47.5 years;
p < 0.01) and black group (48.2 y; p < 0.01). The majority
of patients were white and male in each region.
Notably, over 50 % of blacks with AH were in the
lowest quintile of income (55.4 %). In both blacks and
Hispanics, Medicaid and self-pay (no insurance) were
the most common insurance/payer status. There were
also significant racial/ethnic differences in clinical char-
acteristics. Blacks with AH were more likely than
whites with AH to carry a diagnosis of HCV (10.0 % v
7.9 %; p < 0.01). Hispanics with AH were more likely
than whites with AH to have a gastrointestinal bleed
during hospitalization (2.9 % v. 1.8 %; p < 0.01).
Decompensated cirrhosis was more common in
whites with AH (16.0 %) and Hispanics with AH
(15.0 %) than in blacks with AH (8.6 %).
Outcomes and resource utilization
As demonstrated in Table 2, there were differences in
utilization of hospital resources by race/ethnicity. Mean
THC over the course of an inpatient hospitalization was
significantly higher among Hispanics ($42,387) than
among blacks ($33,359; p < 0.01). Mean LOS was longer
among whites (6.5 d) compared to blacks (5.4 d) and
Hispanics (5.9 d). The mean aggregate number of in-
patient procedures performed was higher among whites
than blacks (1.3 v. 1.1, p < 0.01) but similar between
whites and Hispanics (1.3 v. 1.3, p = 0.16). Inpatient
hospital mortality was lowest for blacks (2.3 %) and
significantly lower in this racial group than for whites
(4.5 %) (p<0.01) and Hispanics (3.9 %) (p<0.01). Only 4
liver transplants were reported in the entire sample.
Given this low number, we did not compare this out-
come by race/ethnicity.
Predictors of inpatient mortality
Table 3 provides significant predictors of inpatient mor-
tality for hospitalized patients with AH in controlled
models. Blacks were significantly less likely than whites
to die while hospitalized for AH (adjusted OR = 0.50;
95 % CI = 0.32–0.78). Hispanics and whites had similar
inpatient mortality. Additional significant predictors of
inpatient mortality included increasing age, increasing
Charlson index, severe cirrhosis, and greater than zero
inpatient procedures performed during the current ad-
mission (Table 3).
Predictors of total hospital costs
Table 4 provides results for the predictor model for
THC. When controlling for demographic and clinical
factors, Hispanic ethnicity was associated with a 1.25-
fold increase in THC when compared to white race.
Thus, on average, a Hispanic patient admitted with AH
had a THC 125 % that of a white patient admitted for
the same duration of time. Despite this difference in
whites and Hispanics, the THC in blacks was compar-
able to the THC in whites. Age, income, payer status,
Charlson index, NPR, and hospitalization in the western
U.S. were also significant predictors of inpatient costs.
Discussion
The cost of care and high resource utilization associated
with AH is significant as demonstrated both in our study
and in previous analyses [1]. However, there is currently
little knowledge about variation in healthcare utilization
and outcomes by race and ethnicity in this condition.
This study of a nationally representative sample of
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Table 1 Demographic and clinical characteristics of patients hospitalized with alcoholic hepatitis from 2008–2011; N = 11,304a,b
Parameter White n = 7019
(61.9 %)
Black n = 1103
(9.8 %)
Hispanic n = 1088
(9.7 %)
Other n = 548
(4.9 %)
Totala
Male Sex (%) 4093 (58.4) 665 (60.4) 894 (82.3) 378 (69.2) 7015 (62.1)
Mean Age, y (s.d) 47.5 (11.0) 48.2 (10.5) 43.7 (11.1) 44.8 (11.6) 47.0 (11.0)
Income (%)
0–25 % 1428 (20.4) 607 (55.4) 366 (33.9) 177 (32.8) 3062 (27.2)
26–50 % 1845 (26.3) 223 (20.0) 248 (22.8) 102 (18.8) 2874 (25.4)
51–75 % 1837 (26.2) 147 (13.3) 250 (22.4) 110 (19.7) 2703 (23.8)
76–100 % 1707 (24.3) 78 (7.0) 157 (14.7) 117 (20.9) 2278 (20.1)
Payer (%)
Medicare 972 (13.9) 191 (17.3) 103 (9.5) 58 (10.3) 1549 (13.7)
Medicaid 1345 (19.2) 338 (30.9) 301 (28.0) 163 (29.8) 2500 (22.2)
Private 2412 (34.4) 193 (17.3) 204 (18.6) 142 (25.9) 3441 (30.5)
Self-pay 1605 (22.7) 298 (26.9) 330 (30.4) 126 (23.1) 2703 (23.8)
Other 661 (9.3) 75 (6.9) 149 (13.4) 58 (10.9) 1063 (9.4)
Admission Source (%)
Emergency room 1449 (20.3) 168 (15.1) 409 (37.2) 105 (18.7) 2238 (19.6)
Outside hospital 63 (0.9) 2 (0.2) 15 (1.4) 8 (1.4) 94 (0.8)
Non-health facility 16 (0.2) 2 (0.2) 0 (0.0) 2 (0.4) 21 (0.2)
Other health facility 477 (6.8) 103 (9.3) 48 (4.4) 32 (5.7) 693 (6.7)
Source unknown 5014 (71.8) 828 (75.2) 616 (57.1) 401 (73.9) 8258 (73.3)
Disposition (%)
Home/Home with aid 4821 (68.8) 849 (77.3) 656 (60.8) 392 (71.8) 7927 (70.3)
Other inpatient facility 746 (10.7) 73 (6.7) 51 (4.7) 34 (6.3) 1115 (9.9)
Other 440 (6.3) 34 (3.1) 42 (3.9) 36 (6.7) 669 (5.9)
Unknown 1012 (14.3) 147 (12.9) 339 (30.5) 86 (15.3) 1593 (13.9)
Mean Charlson Index Score (s.d.) 1.7 (1.9) 1.4 (1.8) 1.6 (1.8) 1.6 (1.9) 1.6 (1.8)
Severity of Liver Disease (%)
No cirrhosis 4913 (70.1) 869 (78.7) 773 (67.2) 377 (69.0) 8007 (70.9)
Compensated Cirrhosis 981 (13.9) 139 (12.7) 192 (17.8) 76 (13.8) 1608 (14.2)
Decompensated Cirrhosis 1125 (16.0) 95 (8.6) 163 (15.0) 95 (17.2) 1689 (14.9)
Known Hepatitis C (%) 556 (7.9) 121 (10.0) 87 (8.2) 35 (6.3) 921 (8.1)
Sepsis (%) 199 (2.9) 27 (2.4) 24 (2.2) 13 (2.4) 294 (2.6)
Gastrointestinal Bleed (%) 126 (1.8) 22 (2.0) 31 (2.9) 13 (2.3) 241 (2.1)
Ascites (%) 2030 (28.9) 165 (15.0) 251 (23.2) 161 (29.3) 3027 (26.7)
Hepatic Encephalopathy (%) 1066 (15.1) 90 (8.1) 126 (11.5) 65 (11.9) 1602 (14.1)
Any infection (%) 1792 (25.6) 226 (20.5) 222 (20.1) 128 (23.5) 2756 (24.3)
Hospital Type/Setting (%)
Teaching 2947 (42.4) 646 (59.6) 597 (56.4) 289 (55.4) 5283 (47.4)
Urban 6209 (89.7) 994 (91.8) 1041 (97.0) 471 (89.8) 10014 (89.9)
U.S. Hospital Region (%)
Northeast 1610 (23.5) 293 (27.4) 250 (23.5) 123 (22.4) 2314 (20.9)
Midwest 1118 (16.0) 180 (16.3) 76 (7.1) 82 (14.9) 2387 (21.2)
South 2614 (37.0) 527 (47.3) 313 (28.6) 146 (26.2) 3969 (34.8)
West 1677 (23.5) 103 (9.1) 449 (40.9) 197 (36.6) 2634 (23.1)
Other race refers to subjects with Asian, Pacific islander, Native American, or another race
y years
aRace/ethnicity was unknown for 1546 individuals not included in this table
bData presented as unweighted n (weighted %) or mean (s.d.)
Weighted % in columns add to 100 %
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hospitalized patients with AH contributes several novel
findings regarding the relationships between race, out-
comes and resource utilization. First, we demonstrated a
higher average THC among Hispanics than whites and
blacks. Secondly, we identified black race as an inde-
pendent predictor for lower inpatient mortality com-
pared to white race in patients hospitalized with AH.
Hispanic patients were shown to incur the highest
charges in the nation, at 1.25 times higher than whites
after adjusting for other factors including SES and payer
source. These results are consistent with previous findings
regarding other disease states that identified an association
between Hispanic ethnicity and increased in-hospital ser-
vice utilization, particularly for conditions characterized
by organ failure and end-of-life [24–26]. Prior studies have
further demonstrated that undocumented and uninsured
Americans have poor access to timely medical care, par-
ticularly Hispanics who disproportionately live below the
poverty line [27], and who may face exposure to unhealthy
social and physical environments and lack of access to
healthcare services [28–33]. Pervasive disparities in access
to preventive services and primary care [29, 30, 32], as
well as presentation with late-stage disease [34–36], likely
contribute to increased resource utilization during in-
patient hospitalization among Hispanics.
Differential use of the emergency room (ER) may also
partially explain our findings of higher THC in
Hispanics. We found that Hispanics utilized the ER as
the source of admission significantly more frequently
than whites or blacks. Consistent with other studies, ER-
based referrals for inpatient hospitalizations are associ-
ated with higher THC [37]. Additionally, Hispanic
patients who report alcohol use utilize ER services for
the care of alcohol related consequences such as
AH more commonly than non-Hispanics [38–40].
The finding that black patients with AH had lower ad-
justed mortality compared to other racial/ethnic groups
is also notable. One possible explanation for this finding
is that blacks do not have as severe a presentation of AH
as compared to other race/ethnic groups. Previous
findings from a single-center investigation demonstrated
blacks (0 %) had a significantly lower proportion of
patients presenting with severe AH, defined as discrim-
inant function > 32, when compared to whites (39 %)
and Hispanics (57 %) [14]. Although this previous study
did not examine inpatient mortality, it can be inferred
Table 2 Healthcare utilization and mortality outcomes by race/ethnicitya,b
White Black Hispanic Other Total P value
W v B
P value
W v H
P value
B v H
THC, $
Mean 38,965.68 33,358.73 42,386.95 42,032.85 37,978.69 <0.01 0.09 <0.01
Median 23,399.00 20,585.54 25,530.00 24,094.00 23,020.00
(IQR) (41,903–13,915) (37,782–11,944) (43,287–15,110) (44,952–13,444) (40,607–13,501)
LOS, d
Mean 6.5 5.4 5.9 6.9 6.3 <0.01 0.01 0.04
Median 4 4 4 4 4
(IQR) (8–3) (7–2) (7–2) (8–3) (8–3)
NPR
Mean 1.3 1.1 1.3 1.5 1.3 <0.01 0.21 0.16
Median 1 0 1 1 1
(IQR) (2–0) (1–0) (2–0) (2–0) (2–0)
Nasogastric tube (%) 26 (0.3) 3 (0.3) 5 (0.5) 2 (0.4) 43 (0.4) 0.67 0.60 0.48
Mechanical Ventilation (%) 241 (3.4) 34 (3.1) 34 (3.1) 24 (4.5) 385 (3.4) 0.54 0.62 0.93
Hemodialysis (%) 3 (<0.1) 0 (0) 1 (<0.1) 1 (0.2) 8 (<0.1) – 0.53 –
Liver biopsy (%) 241 (3.4) 34 (3.2) 27 (2.5) 14 (3.1) 355 (3.2) 0.68 0.10 0.32
Paracentesis (%) 1259 (17.8) 103 (9.2) 154 (14.2) 94 (17.2) 1887 (16.6) <0.001 <0.001 <0.001
EGD (%) 1111 (15.9) 153 (13.7) 161 (14.8) 86 (15.7) 1784 (15.8) 0.06 0.40 0.43
Deaths (%) 315 (4.5) 25 (2.3) 43 (3.9) 29 (5.3) 489 (4.3) <0.001 0.38 0.03
Other race refers to subjects with Asian, Pacific islander, Native American, or another race
W white, B black, H hispanic, THC total hospital costs, LOS length of stay, NPR number of procedures, IQR interquartile range, EGD esophagogastroduodenoscopy
aTotal hospital costs for 2008, 2009, and 2010 are inflated to 2011 values
b% values are weighted to national population estimates
– there were no black subjects with hemodialysis
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that the milder disease presentation among blacks would
lead to a lower rate of death during hospitalization [14].
Our study, using a nationwide database, may support
this hypothesis. Another explanation for lower inpatient
mortality among blacks may be related to differences in
provider care patterns between blacks and non-blacks.
Studies in the literature have demonstrated lower
inpatient mortality in blacks compared to whites for
Table 3 Predictors of inpatient mortality in patients with AH
Predictor Died % (n = 489) Odds Ratio (95 % CI)
Age – 1.02 (1.01–1.03)***
Sex
Male 322 (4.6) Reference
Female 167 (3.9) 0.83 (0.67–1.01)
Race/Ethnicity
White 315 (4.5) Reference
Black 25 (2.3) 0.50 (0.32–0.78)**
Hispanic 43 (3.9) 0.89 (0.61–1.30)
Other 29 (5.3) 1.07 (0.70–1.66)
Income
Lowest 25 % 139 (4.5) 1.21 (0.92–1.60)
25–50 % 122 (4.3) Reference
50–75 % 117 (4.3) 1.06 (0.81–1.38)
75–100 % 97 (4.3) 0.87 (0.65–1.16)
Charlson comorbidity – 1.41 (1.34–1.49)***
Severity of liver disease
No cirrhosis 260 (3.3) Reference
Stage 1–2 78 (4.9) 0.79 (0.58–1.07)
Stage 3–4 151 (9.0) 0.77 (0.59–0.99)*
Teaching Hospital
No 234 (4.0) 0.96 (0.77–1.20)
Yes 245 (4.6) Reference
Hospital setting
Urban 432 (4.3) Reference
Rural 47 (4.2) 0.89 (0.62–1.28)
Number of Procedures
0 Reference
1 54 (1.9) 1.53 (1.03–2.23)*
2 54 (3.8) 2.79 (1.83–4.25)***
> 2 332 (17.4) 13.3 (9.57–18.41)***
Data are presented as n (%) or odds ratios (95 % CI)
Final logistic regression model included survey weights and the following
variables: sex, age, race/ethnicity, income, Charlson comorbidity score, severity
of liver disease, teaching hospital status, hospital location, and number of
inpatient procedures
Other race refers to subjects with Asian, Pacific islander, Native American, or
another race
CI confidence interval
*P <0.05; **P <0.01; ***P <0.001
Table 4 Predictors of inpatient THC in patients with AH
Predictor Factor (fold increase) 95 % Confidence Interval
Age 0.99 0.98–0.99*
Sex
Male Reference
Female 1.03 0.94–1.15
Race/Ethnicity
White Reference
Black 1.24 0.96–1.60
Hispanic 1.25 1.01–1.49*
Other 0.94 0.79–1.13
Income
Lowest 25 % 0.93 0.76–1.13
25–50 % Reference
50–75 % 1.07 0.92–1.25
75–100 % 1.18 1.03–1.34*
Payer
Medicaid 0.85 0.73–0.98*
Medicare 0.94 0.81–1.09
Private Reference
Self-pay 0.75 0.62–0.91**
Other 0.84 0.72–0.99*
Length of Stay 1.02 1.02–1.03***
Charlson Index 1.04 1.02–1.07***
Severity of liver disease
No cirrhosis Reference
Stage 1–2 1.12 0.97–1.31
Stage 3–4 1.01 0.89–1.15
Number of Procedures
0 Reference
1 1.27 1.20–1.34***
2 1.74 1.53–1.99***
> 2 2.97 2.72–3.25***
Hospital Region
Northeast Reference
Midwest 1.06 0.85–1.33
South 0.88 0.70–1.11
West 1.32 1.02–1.71*
Teaching Hospital
No Reference
Yes 1.10 0.94–1.28
Hospital setting
Urban 1.28 1.11–1.48***
Rural Reference
Parameter coefficients are presented as a fold increase with 95 % CI
Final general linear model included survey weights and the following,
variables: age, sex, race/ethnicity, income, payer, length of inpatient stay,
Charlson comorbidity score, severity of liver disease, hospital region, teaching
hospital status, hospital location, and number of inpatient procedures
Other race refers to subjects with Asian, Pacific islander, Native American, or
another race
CI confidence interval
*P <0.05; **P <0.01; ***P <0.001
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several conditions, which may be due to variation in
quality of care or disease management and, possibly,
earlier discharge and/or greater out of hospital mortality
among blacks [41–43]. Our data source limited our
ability to investigate these hypotheses; however, future
studies should explore these potential explanations.
Our data must be interpreted in the context of the
study’s limitations. First, NIS does not provide access to
anthropometric or laboratory data. Such limitations
might explain the relatively low rate of HCV seen in our
AH cohort as HCVAb and HCV-RNA status may not
have been known for all study subjects. It also limited us
from distinguishing between non-severe AH and severe
AH by calculating a discriminant function. However, we
were able to account for comorbid medical conditions
and severity of hepatic decompensation using the
Charlson comorbidity score and Baveno IV measure. In
doing so, we aimed to control for overall co-morbidity
and liver disease severity, regardless of etiology. An add-
itional limitation in our study was the inability to make
conclusions about resource utilization and mortality for
members of small race/ethnic groups (Asians, Pacific Is-
landers, Native Americans). As each of these groups was
small, they were combined to create a heterogeneous
‘other race’ category. As a result, we were unable to
analyze each of these groups separately. Lastly, as our
study is a cross-sectional, observational study based
on secondary data, we are unable to make conclu-
sions about causation. These limitations are mitigated,
however, by use of a large, nationally-representative
database that enhances the generalizability of our re-
sults. Based on our findings, we suggest additional
analyses to assess physician practice patterns in the
management of AH patients, with attention to expla-
nations for why racial and ethnic differences in
mortality and resource utilization exist.
Conclusions
In conclusion, our study demonstrated significant vari-
ation in inpatient mortality and inpatient costs between
whites and racial/ethnic minorities hospitalized for AH
in the U.S. Hispanics admitted for AH had similar mor-
tality to but higher associated costs than whites
admitted for AH. Blacks hospitalized for AH had lower
inpatient mortality but similar inpatient costs to whites
hospitalized for the same condition. We suspect that the
differences in morality, cost, and resource utilization
observed reflect multiple factors, including differences in
access to care, comorbidity, AH severity at presentation,
and quality of care delivered. Further investigation is
warranted regarding the specific patient-, provider-, and
system-level factors driving these findings to improve
clinical outcomes, improve health equity, and curtail
high healthcare costs.
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